# A Study to Evaluate Bioequivalence and Adhesion of a Transdermal Contraceptive Patch Manufactured With Newly Sourced Adhesive Components and Currently Marketed EVRA in Healthy Adult Women

> **NCT03274297** · PHASE4 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 70 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** EVRA patch (NGMN+EE) (Treatment A) (Reference)
- **DRUG:** HMW PIB patch (NGMN+EE) (Treatment B) (Test)

## Key facts

- **NCT ID:** NCT03274297
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-20
- **Primary completion:** 2018-05-07
- **Final completion:** 2018-05-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03274297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03274297, "A Study to Evaluate Bioequivalence and Adhesion of a Transdermal Contraceptive Patch Manufactured With Newly Sourced Adhesive Components and Currently Marketed EVRA in Healthy Adult Women". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03274297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*